Publication | Closed Access

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Dolutegravir Versus DarunavirOpen-label Phase 3BTreatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirologyPharmacotherapyAntiviral DrugHivMedicineEpidemiologyWeek Results